HY-147239-10mg
|
MedChemexpress LLC
|
MC-VA-PABC-MMAE [CAS 1818864-51-5]
|
|
Cancer-programmed cell death
|
|
HY-147239-5mg
|
MedChemexpress LLC
|
MC-VA-PABC-MMAE [CAS 1818864-51-5]
|
|
Cancer-programmed cell death
|
|
HY-147270-10mg
|
MedChemexpress LLC
|
MC-VA-PAB-Exatecan [CAS 2680543-57-9]
|
|
Cancer-programmed cell death
|
|
HY-147270-100mg
|
MedChemexpress LLC
|
MC-VA-PAB-Exatecan [CAS 2680543-57-9]
|
|
Cancer-programmed cell death
|
|
HY-147270-5mg
|
MedChemexpress LLC
|
MC-VA-PAB-Exatecan [CAS 2680543-57-9]
|
|
Cancer-programmed cell death
|
|
HY-147270-50mg
|
MedChemexpress LLC
|
MC-VA-PAB-Exatecan [CAS 2680543-57-9]
|
|
Cancer-programmed cell death
|
|
HY-107663A-100mg
|
MedChemexpress LLC
|
MIF-1 (TFA) [CAS 35240-69-8]
|
|
Cancer-programmed cell death
|
|
HY-107663A-25mg
|
MedChemexpress LLC
|
MIF-1 (TFA) [CAS 35240-69-8]
|
|
Cancer-programmed cell death
|
|
HY-107663A-50mg
|
MedChemexpress LLC
|
MIF-1 (TFA) [CAS 35240-69-8]
|
|
Cancer-programmed cell death
|
|
HY-107663A-1mL
|
MedChemexpress LLC
|
MIF-1 (TFA) [CAS 35240-69-8] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
HY-12220A-10mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-2mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-5mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-50mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-1mL
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
HY-P3412-10mg
|
MedChemexpress LLC
|
MMI-0100 [CAS 1039342-24-9]
|
|
COVID-19-immunoregulation
|
|
HY-P3412-25mg
|
MedChemexpress LLC
|
MMI-0100 [CAS 1039342-24-9]
|
|
COVID-19-immunoregulation
|
|
HY-P3412-5mg
|
MedChemexpress LLC
|
MMI-0100 [CAS 1039342-24-9]
|
|
COVID-19-immunoregulation
|
|
sc-3093
|
Santa Cruz Biotechnology
|
PKC peptide inhibitor, Cell Permeable
|
|
|
|